Circulating immune cell landscape and T-cell abnormalities in patients with moyamoya disease

Abstract

Background: Moyamoya disease (MMD) stands as a prominent cause of stroke among children and adolescents in East Asian populations. Although a growing body of evidence suggests that dysregulated inflammation and autoimmune responses might contribute to the development of MMD, a comprehensive and detailed understanding of the alterations in circulating immune cells associated with MMD remains elusive.

Methods: In this study, we employed a combination of single-cell RNA sequencing (scRNA-seq), mass cytometry and RNA-sequencing techniques to compare immune cell profiles in peripheral blood samples obtained from patients with MMD and age-matched healthy controls.

Results: Our investigation unveiled immune dysfunction in MMD patients, primarily characterized by perturbations in T-cell (TC) subpopulations, including a reduction in effector TCs and an increase in regulatory TCs (Tregs). Additionally, we observed diminished natural killer cells and dendritic cells alongside heightened B cells and monocytes in MMD patients. Notably, within the MMD group, there was an augmented proportion of fragile Tregs, whereas the stable Treg fraction decreased. MMD was also linked to heightened immune activation, as evidenced by elevated expression levels of HLA-DR and p-STAT3.

Conclusions: Our findings offer a comprehensive view of the circulating immune cell landscape in MMD patients. Immune dysregulation in patients with MMD was characterized by alterations in T-cell populations, including a decrease in effector T-cells and an increase in regulatory T-cells (Tregs), suggest a potential role for disrupted circulating immunity in the aetiology of MMD.

Keywords

immune dysfunction / landscape / moyamoya disease / T-cell abnormalities

References

[1] Kuroda S, Houkin K. Moyamoya disease: current concepts and future perspectives. Lancet Neurol. 2008;7(11):1056-1066.

[2] Ihara M, Yamamoto Y, Hattori Y, et al. Moyamoya disease: diagnosis and interventions. Lancet Neurol. 2022;21(8):747-758.

[3] Kim JS. Moyamoya disease: epidemiology, clinical features, and diagnosis. J Stroke. 2016;18(1):2-11.

[4] Fujimura M, Sonobe S, Nishijima Y, et al. Genetics and biomarkers of moyamoya disease: significance of RNF213 as a susceptibility gene. J Stroke. 2014;16(2):65-72.

[5] Bang OY, Fujimura M, Kim SK. The pathophysiology of moyamoya disease: an update. J Stroke. 2016;18(1):12-20.

[6] Miyatake S, Miyake N, Touho H, et al. Homozygous c.14576G>a variant of RNF213 predicts early-onset and severe form of moyamoya disease. Neurology. 2012;78(11):803-810.

[7] Zhang Q, Liu Y, Zhang D, et al. RNF213 as the major susceptibility gene for Chinese patients with moyamoya disease and its clinical relevance. J Neurosurg. 2017;126(4):1106-1113.

[8] Wang Y, Zhang Z, Wei L, et al. Predictive role of heterozygous p.R4810K of RNF213 in the phenotype of Chinese moyamoya disease. Neurology. 2020;94(7):e678-e686.

[9] Mikami T, Suzuki H, Komatsu K, Mikuni N. Influence of inflammatory disease on the pathophysiology of moyamoya disease and quasi-moyamoya disease. Neurol Med Chir (Tokyo). 2019;59(10):361-370.

[10] Han W, Qiao Y, Zhang H, et al. Circulating sortilin levels are associated with inflammation in patients with moyamoya disease. Metab Brain Dis. 2021;36(1):103-109.

[11] Jin F, Duan C. Identification of immune-infiltrated hub genes as potential biomarkers of moyamoya disease by bioinformatics analysis. Orphanet J Rare Dis. 2022;17(1):80.

[12] Liu E, Liu C, Jin L, et al. Clinical value of the systemic immune-inflammation index in moyamoya disease. Front Neurol. 2023;14:1123951.

[13] Liu W, Sun J, Shi Z, et al. Circulating inflammatory cytokine associated with poor prognosis in moyamoya disease: a prospective cohort study. J Clin Med. 2023;12(3):823.

[14] Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis, and Health Labour Sciences Research Grant for Research on Measures for Infractable Diseases. Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis). Neurol Med Chir (Tokyo). 2012;52(5):245-266.

[15] Stuart T, Butler A, Hoffman P, et al. Comprehensive integration of single-cell data. Cell. 2019;177:1888-1902.e21.

[16] Der E, Ranabothu S, Suryawanshi H, et al. Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis. JCI Insight. 2017;2:e93009.

[17] Der E, Suryawanshi H, Morozov P, et al. Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. Nat Immunol. 2019;20:915-927.

[18] He H, Suryawanshi H, Morozov P, et al. Single-cell transcriptome analysis of human skin identifies novel fibroblast subpopulation and enrichment of immune subsets in atopic dermatitis. J Allergy Clin Immunol. 2020;145:1615-1628.

[19] Zheng Y, Liu X, Le W, et al. A human circulating immune cell landscape in aging and COVID-19. Protein Cell. 2020;11:740-770.

[20] Lužnik Z, Anchouche S, Dana R, Yin J. Regulatory T cells in angiogenesis. J Immunol. 2020;205(10):2557-2565.

[21] Overacre-Delgoffe AE, Vignali D. Treg fragility: a prerequisite for effective antitumor immunity. Cancer Immunol Res. 2018;6(8):882-887.

[22] Sakaguchi S, Mikami N, Wing JB, Tanaka A, Ichiyama K, Ohkura N. Regulatory T cells and human disease. Annu Rev Immunol. 2020;38:541-566.

[23] Scheinecker C, Göschl L, Bonelli M. Treg cells in health and autoimmune diseases: new insights from single cell analysis. J Autoimmun. 2020;110:102376.

[24] Zappasodi R, Serganova I, Cohen IJ, et al. CTLA-4 blockade drives loss of T(reg) stability in glycolysis-low tumours. Nature. 2021;591(7851):652-658.

[25] Inoue TK, Ikezaki K, Sasazuki T, Matsushima T, Fukui M. Analysis of class II genes of human leukocyte antigen in patients with moyamoya disease. Clin Neurol Neurosurg. 1997;99(2):S234-S237.

[26] Wan J, Ling W, Zhengshan Z, Xianbo Z, Lian D, Kai W. Association of HLA-DQA2 and HLA-B with moyamoya disease in the Chinese Han population. Neurol Genet. 2021;7(3):e592.

[27] Chapman NM, Boothby MR, Chi H. Metabolic coordination of T cell quiescence and activation. Nat Rev Immunol. 2020;20(1):55-70.

[28] Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12(6):492-499.

[29] Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486-499.

[30] Kanoke A, Fujimura M, Niizuma K, et al. Temporal profile of magnetic resonance angiography and decreased ratio of regulatory T cells after immunological adjuvant administration to mice lacking RNF213, a susceptibility gene for moyamoya disease. Brain Res. 2016;1642:1-9.

[31] Mejia-Munne JC, Ellis JA, Feldstein NA, Meyers PM, Connolly ES. Moyamoya and Inflammation. World Neurosurg. 2017;100:575-578.

[32] Weng L, Cao X, Han L, et al. Association of increased Treg and Th17 with pathogenesis of moyamoya disease. Sci Rep. 2017;7(1):3071.

[33] Chen T, Wei W, Yu J, et al. The progression of pathophysiology of moyamoya disease. Neurosurgery. 2023;93(3):502-509.

[34] Mineharu Y, Miyamoto S. RNF213 and GUCY1A3 in moyamoya disease: key regulators of metabolism, inflammation, and vascular stability. Front Neurol. 2021;12:687088.

[35] Jeong J, Choi YJ, Lee HK. The role of autophagy in the function of CD4(+) T cells and the development of chronic inflammatory diseases. Front Pharmacol. 2022;13:860146.

[36] Künzli M, Masopust D. CD4(+) T cell memory. Nat Immunol. 2023;16(5):295-303.

[37] Grönberg C, Nilsson J, Wigren M. Recent advances on CD4(+) T cells in atherosclerosis and its implications for therapy. Eur J Pharmacol. 2017;816:58-66.

[38] Saigusa R, Winkels H, Ley K. T cell subsets and functions in atherosclerosis. Nat Rev Cardiol. 2020;17(7):387-401.

[39] Tashiro R, Niizuma K, Kasamatsu J, et al. Dysregulation of Rnf 213 gene contributes to T cell response via antigen uptake, processing, and presentation. J Cell Physiol. 2021;236:7554-7564.

[40] Aoyagi M, Ogami K, Matsushima Y, Shikata M, Yamamoto M, Yamamoto K. Human leukocyte antigen in patients with moyamoya disease. Stroke. 1995;26:415-417.

[41] Kraemer M, Horn PA, Roder C, et al. Analysis of human leucocyte antigen genes in Caucasian patients with idiopathic moyamoya angiopathy. Acta Neurochir (Wien). 2012;154:445-454.

[42] Liang Z, Wu G, Fan C, et al. The emerging role of signal transducer and activator of transcription 3 in cerebral ischemic and hemorrhagic stroke. Prog Neurobiol. 2016;137:1-16.

[43] Göschl L, Scheinecker C, Bonelli M. Treg cells in autoimmunity: from identification to Treg-based therapies. Semin Immunopathol. 2019;41(3):301-314.

[44] Ohkura N, Sakaguchi S. Transcriptional and epigenetic basis of Treg cell development and function: its genetic anomalies or variations in autoimmune diseases. Cell Res. 2020;30(6):465-474.

[45] Zhang L, Rashad S, Zhou Y, Niizuma K, Tominaga T. RNF213 loss of function reshapes vascular transcriptome and spliceosome leading to disrupted angiogenesis and aggravated vascular inflammatory responses. J Cereb Blood Flow Metab. 2022;42:2107-2122.

[46] Wang HY, Ye JR, Cui LY, Chu SF, Chen NH. Regulatory T cells in ischemic stroke. Acta Pharmacol Sin. 2022;43(1):1-9.

[47] Wang M, Thomson AW, Yu F, Hazra R, Junagade A, Hu X. Regulatory T lymphocytes as a therapy for ischemic stroke. Semin Immunopathol. 2023;45:329-346.

[48] Pucino V, De Rosa V, Procaccini C, Matarese G. Regulatory T cells, leptin and angiogenesis. Chem Immunol Allergy. 2014;99:155-169.

[49] Lee WS, Yang H, Chon HJ, Kim C. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp Mol Med. 2020;52:1475-1485.

[50] Malone MK, Ujas TA, Britsch D, Cotter KM, Poinsatte K, Stowe AM. The immunopathology of B lymphocytes during stroke-induced injury and repair. Semin Immunopathol. 2023;45:315-327.

[51] Peng X, Zhang Z, Ye D, et al. Gene dysregulation in peripheral blood of moyamoya disease and comparison with other vascular disorders. PLoS One. 2019;14:e0221811.

[52] Masuda J, Ogata J, Yutani C. Smooth muscle cell proliferation and localization of macrophages and T cells in the occlusive intracranial major arteries in moyamoya disease. Stroke. 1993;24:1960-1967.

[53] Xu Y, Kovacic JC. Endothelial to mesenchymal transition in health and disease. Annu Rev Physiol. 2023;85:245-267.

[54] Kovacic JC, Dimmeler S, Harvey RP, et al. Endothelial to mesenchymal transition in cardiovascular disease: jACC state-of-the-art review. J Am Coll Cardiol. 2019;73(2):190-209.

[55] Souilhol C, Harmsen MC, Evans PC, Krenning G. Endothelial-mesenchymal transition in atherosclerosis. Cardiovasc Res. 2018;114:565-577.

[56] Gorelova A, Berman M, Al Ghouleh I. Endothelial-to-mesenchymal transition in pulmonary arterial hypertension. Antioxid Redox Signal. 2021;34:891-914.

[57] Cheng W, Li X, Liu D, Cui C, Wang X. Endothelial-to-mesenchymal transition: role in cardiac fibrosis. J Cardiovasc Pharmacol Ther. 2021;26:3-11.

[58] Amyere M, Revencu N, Helaers R, et al. Germline loss-of-function mutations in EPHB4 cause a second form of capillary malformation-arteriovenous malformation (CM-AVM2) deregulating RAS-MAPK signaling. Circulation. 2017;136(11):1037-1048.

[59] Xu Z, Rui YN, Hagan JP, Kim DH. Intracranial aneurysms: pathology, genetics, and molecular mechanisms. Neuromolecular Med. 2019;21(4):325-343.

[60] Mertens R, Graupera M, Gerhardt H, et al. The genetic basis of moyamoya disease. Transl Stroke Res. 2022;13(1):25-45.

[61] Hongo H, Miyawaki S, Teranishi Y, et al. Genetics of brain arteriovenous malformations and cerebral cavernous malformations. J Hum Genet. 2023;68:157-167.

[62] Snellings DA, Hong CC, Ren AA, et al. Cerebral cavernous malformation: from mechanism to therapy. Circ Res. 2021;129:195-215.

[63] Nemazanyy I, Blaauw B, Paolini C, et al. Defects of Vps15 in skeletal muscles lead to autophagic vacuolar myopathy and lysosomal disease. EMBO Mol Med. 2013;5:870-890.

[64] Laurent D, Small C, Lucke-Wold B, et al. Understanding the genetics of intracranial aneurysms: a primer. Clin Neurol Neurosurg. 2022;212:107060.

[65] Maddy K, Chalamgari A, Ariwodo O, Nisseau-Bey Z, Maldonado J, Lucke-Wold B. An updated review on the genetics of arteriovenous malformations. Gene Protein Dis. 2023;2(2):0312.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.